. intolerance). Ibrutinib is the current gold typical therapy for patients with relapsed/refractory disease, according to the results of numerous phase I-III trials, one hundred fifteen–119 but This really is also transforming for 2 main explanations: (i) an ever-increasing proportion of individuals at the moment obtain ibrutinib as frontline the